

# Annexes

## Les chiffres des publications de l'ICO 2015


**199**  
publications  
et **1 931**  
**POINTS SIGAPS**  
en 2015

## Annexes

### Figures of the publications of the ICO 2015

#### ÉVOLUTION DES PUBLICATIONS DEPUIS 2011

■ Nombre de publications  
■ Points SIGAPS



PARMI LES 199 PUBLICATIONS DE L'ICO, 37 FIGURENT DANS DES REVUES INTERNATIONALES OU D'EXCELLENCE DE SCORE "A" À TRÈS FORT IMPACT FACTOR.

#### NOM DE LA REVUE

The New England Journal of Medecine	3
The Lancet Oncology	11
Journal of Clinical Oncology (JCO)	5
Clinical Cancer Research	4
Annals of Oncology	11
European Journal of Nuclear Medecine and Molecular Imaging	3

## LISTE DES PUBLICATIONS 2015

- 1 Alentorn, A., Dehais, C., Ducray, F., Carpentier, C., Mokhtari, K., Figarella-Branger, D., ... Idbaih, A. (2015). Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. *Neurology*, 85, 1325-1331.
- 2 Aparicio, T., Linot, B., Le Malicot, K., Bouché, O., Boige, V., François, E., ... Bedenne, L. (2015). FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802). *Dig Liver Dis*, 47, 271-272.
- 3 Apetoh, L., Smyth, M. J., Drake, C. G., Abastado, J. P., Apte, R. N., Ayyoub, M., ... Anderson, A. C. (2015). Consensus nomenclature for CD8(+) T cell phenotypes in cancer. *Oncoimmunology*, 4, e998538.
- 4 Ardillon, L., Ternisien, C., Fouassier, M., Sigaud, M., Lefrançois, A., Pacault, M., ... Trossaert, M. (2015). Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year "real-world" experience. *Haemophilia*, 21, 646-652.
- 5 Arsène, E., Bleu, G., Merlot, B., Boulanger, L., Vinatier, D., Kerdraon, O., & Collinet, P. (2015). Implications of a two-step procedure in surgical management of patients with early-stage endometrioid endometrial cancer. *J Gynecol Oncol*, 26, 125-133.
- 6 Azaïs, H., Queniat, G., Bonner, C., Kerdraon, O., Tardivel, M., Jetpisbayeva, G., ... Mordon, S. (2015). Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy. *Int. J. Gynecol. Cancer*, 25, 1194-1200.
- 7 Bard, J. M., Paillard, F., & Lecerf, J. M. (2015). Effect of phytosterols/stanols on LDL concentration and other surrogate markers of cardiovascular risk. *Diabetes Metab.*, 41, 69-75.
- 8 Bataille, R. (2015). The multiple myeloma bone eco-system and its relation to oncogenesis. *Morphologie*, 99, 31-37.
- 9 Baudin, E. (2015). Adrenocortical carcinoma. *Endocrinol. Metab. Clin. North Am.*, 44, 411-434.
- 10 Bazin, C., Poirier, A. L., & Dupouiron, D. (2015). Influence of pH and temperature on ziconotide stability in intrathecal analgesic admixtures in implantable pumps and syringes. *Int J Pharm*, 487, 285-291.
- 11 Bennouna, J., Deslandres, M., Senellart, H., de Labareyre, C., Ruiz-Soto, R., Wixon, C., ... Delord, J. P. (2015). A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. *Invest New Drugs*, 33, 138-147.
- 12 Berger, C., El Fayech, C., Pacquement, H., Demoor-Goldschmidt, C., Ducassou, S., Ansoberlo, S., & Defachelles, A. S. (2015). [Objectives and organization for the long-term follow-up after childhood cancer]. *Bull Cancer*, 102, 579-585.
- 13 Besse, B., Le Moulec, S., Mazières, J., Senellart, H., Barlesi, F., Chouaid, C., ... Soria, J. C. (2015). Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. *Clin. Cancer Res.*, 21, 1896-1903.
- 14 Beydon, L., Rouxel, A., Camut, N., Schinkel, N., Malinovsky, J. M., Aveline, C., ... Alberti, C. (2015). Sedative premedication before surgery--A multicentre randomized study versus placebo. *Anaesth Crit Care Pain Med*, 34, 165-171.
- 15 Blanchecotte, J., Ruffier-Loubière, A., Reynaud-Bougnoux, A., & Barillot, I. (2015). [Acute skin toxicity in breast intensity modulated radiotherapy using field in field technique]. *Cancer Radiother*, 19, 82-88.
- 16 Blanchin, M., Guilleux, A., Perrot, B., Bonnaud-Antignac, A., Hardouin, J. B., & Sébille, V. (2015). Power and sample size determination for the group comparison of patient-reported outcomes using the Rasch model: impact of a misspecification of the parameters. *BMC Med Res Methodol*, 15, 21.
- 17 Blanco, I., Kuchenbaecker, K., Cuadras, D., Wang, X., Barrowdale, D., de Garibay, G. R., ... Pujana, M. A. (2015). Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, 10, e0120020.
- 18 Blay, J. Y., Pápai, Z., Tolcher, A. W., Italiano, A., Cupissol, D., López-Pousa, A., ... Demetri, G. D. (2015). Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.*, 16, 531-540.
- 19 Bleu, G., Arsène, E., Merlot, B., Kerdraon, O., Bigot, J., Boulanger, L., ... Collinet, P. (2015). How to improve the preoperative staging of presumed early-stage endometrioid endometrial cancer? *Eur. J. Gynaecol. Oncol.*, 36, 698-702.
- 20 Bobin-Dubigeon, C., Lefrançois, A., Classe, J. M., Joalland, M. P., & Bard, J. M. (2015). Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence. *Clin. Biochem.*, 48, 1181-1183.
- 21 Bodet-Milin, C., Ferrer, L., Rauscher, A., Masson, D., Rbah-Vidal, L., Faivre-Chauvet, A., ... Barbet, J. (2015). Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. *Front Med (Lausanne)*, 2, 84.
- 22 Bompas, E., Le Cesne, A., Tresch-Bruneel, E., Lebellec, L., Laurence, V., Collard, O., ... Penel, N. (2015). Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). *Ann. Oncol.*, 26, 2168-2173.
- 23 Borg, J. Y., Négrier, C., Durieu, I., Dolimier, E., Masquelier, A. M., & Lévesque, H. (2015). FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French "FEIBA dans l'hémophilie A acquise" (FEIBHAC) registry. *Haemophilia*, 21, 330-337.
- 24 Borget, I., Bonastre, J., Catargi, B., Déandréis, D., Zerdoud, S., Rusu, D., ... Schlumberger, M. (2015). Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. *J. Clin. Oncol.*, 33, 2885-2892.
- 25 Brocard, E., Oizel, K., Lalier, L., Pecqueur, C., Paris, F., Vallette, F. M., & Oliver, L. (2015). Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling. *Oncotarget*, 6, 6840-6849.
- 26 Buge, F., Chiavassa, S., Hervé, C., Rigaud, J., Delpon, G., & Supiot, S. (2015). Preclinical Evaluation of Intraoperative Low-Energy Photon Radiotherapy Using Spherical Applicators in Locally Advanced Prostate Cancer. *Front Oncol*, 5, 204.

- 27 Burdett, S., Pignon, J. P., Tierney, J., Tribodet, H., Stewart, L., Le Pechoux, C., ... Liang, Y. (2015). Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. *Cochrane Database Syst Rev*, 3, CD011430.
- 28 Campone, M., Valo, I., Jézéquel, P., Moreau, M., Boissard, A., Campion, L., ... Guette, C. (2015). Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples. *Mol. Cell Proteomics*, 14, 2936-2946.
- 29 Cassier, P. A., Italiano, A., Gomez-Roca, C. A., Le Tourneau, C., Toulmonde, M., Cannarile, M. A., ... Rüttinger, D. (2015). CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. *Lancet Oncol.*, 16, 949-956.
- 30 Chapelet, G., Berrut, G., Bourbouloux, E., Campone, M., Derkinderen, P., & de Decker, L. (2015). [Cancer screening practices in elderly with dementia]. *Geriatr Psychol Neuropsychiatr Vieil*, 13, 133-140.
- 31 Chevallier, P., Eugene, T., Robillard, N., Isnard, F., Nicolini, F., Escoffre-Barbe, M., ... Kraeber-Bodéré, F. (2015). (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. *Lancet Haematol*, 2, e108-117.
- 32 Chiavassa, S., Buge, F., Hervé, C., Delpon, G., Rigaud, J., Lisbona, A., & Supiot, S. (2015). Monte-Carlo evaluation of the effect of inhomogeneities on dose calculation for low energy photons intra-operative radiation therapy in pelvic area. *Phys Med*, 31, 956-962.
- 33 Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., ... Motzer, R. J. (2015). Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.*, 373, 1814-1823.
- 34 Classe, J. M., Glehen, O., Decullier, E., Bereder, J. M., Msika, S., Lorimier, G., ... Bakrin, N. (2015). Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian Cancer. *Anticancer Res.*, 35, 4997-5005.
- 35 Clément-Colmou, K., Troussier, I., Bardet, É., & Lapeyre, M. (2015). [Clinical and paraclinical follow-up after radiotherapy for head and neck cancer]. *Cancer Radiother*, 19, 597-602.
- 36 Clough, K. B., Acosta-Marín, V., Nos, C., Alran, S., Rouanet, P., Garbay, J. R., ... Bonnier, P. (2015). Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey. *Ann. Surg. Oncol.*, 22, 3504-3511.
- 37 Cloutier, A. S., Faron, M., Honoré, C., Goéré, D., Dumont, F., Vittadello, F., & Élias, D. (2015). Second-look surgery plus HIPEC for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Should we resect the initial anastomosis? An observational study. *Eur J Surg Oncol*, 41, 1068-1073.
- 38 Colombié, M., Campion, L., Bailly, C., Rusu, D., Rousseau, T., Mathieu, C., ... Rousseau, C. (2015). Prognostic value of metabolic parameters and clinical impact of <sup>1</sup>F-fluorocholine PET/CT in biochemical recurrent prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging*, 42, 1784-1793.
- 39 Colombié, M., Gouard, S., Frindel, M., Vidal, A., Chérel, M., Kraeber-Bodéré, F., ... Bourgeois, M. (2015). Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging. *Front Med (Lausanne)*, 2, 58.
- 40 Croce, S., Ribeiro, A., Brulard, C., Noel, J. C., Amant, F., Stoeckle, E., ... Chibon, F. (2015). Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. *Mod. Pathol.*, 28, 1001-1010.
- 41 Damiola, F., Schultz, I., Barjhoux, L., Sorin, V., Dondon, M. G., Eon-Marchais, S., ... Muller, D. (2015). Mutation analysis of PALB2 gene in French breast cancer families. *Breast Cancer Res. Treat.*, 154, 463-471.
- 42 Darrieurtot-Laffite, C., Ansqer, C., Maugars, Y., Le Goff, B., Bodere, F., & Berthelot, J. M. (2015). Sodium (18)F-sodium fluoride PET failed to predict responses to TNF $\alpha$  antagonist therapy in 31 patients with possible spondyloarthritis not meeting ASAS criteria. *Joint Bone Spine*, 82, 411-416.
- 43 de Crevoisier, R., Créhange, G., Castelli, J., Lafond, C., & Delpon, G. (2015). [Good practice of image-guided radiotherapy]. *Cancer Radiother*, 19, 489-500.
- 44 de la Rochefordiere, A., Kamal, M., Floquet, A., Thomas, L., Petrow, P., Petit, T., ... Scholl, S. M. (2015). PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy  $\pm$  Cetuximab in Cervical Cancer Patients. *Clin. Cancer Res.*, 21, 2530-2537.
- 45 Delbaldo, C., Ychou, M., Zawadi, A., Douillard, J. Y., André, T., Guerin-Meyer, V., ... Piedbois, P. (2015). Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†. *Ann. Oncol.*, 26, 1208-1215.
- 46 Delpon, G., Chiavassa, S., Supiot, S., Boutry, C., Darréon, J., Desrousseaux, J., ... de Crevoisier, R. (2015). [Image-guided radiotherapy: Overview of devices and practice in France in 2015]. *Cancer Radiother*, 19, 501-507.
- 47 Demoor-Goldschmidt, C., & Bernier, V. (2015). [Towards an improvement of the quality of life after radiotherapy in children]. *Bull Cancer*, 102, 674-683.
- 48 Demoor-Goldschmidt, C., Dumoucel, S., Haie-Meder, C., Corradini, N., Mahé, M. A., & Supiot, S. (2015). Conservative management of a perianal rhabdomyosarcoma in a 2-year old child by Papillon's technique. *Radiat Oncol*, 10, 108.
- 49 Demoor-Goldschmidt, C., Fayeche, C., Girard, P., & Plantaz, D. (2015). [Secondary cancers: Incidence, risk factors and recommendations]. *Bull Cancer*, 102, 656-664.
- 50 Denis, F., Yossi, S., Septans, A. L., Charron, A., Voog, E., Dupuis, O., ... Letellier, C. (2015). Improving Survival in Patients Treated for a Lung Cancer Using Self-Evaluated Symptoms Reported Through a Web Application. *Am. J. Clin. Oncol.*
- 51 Derrien, A., Gouard, S., Maurel, C., Gaugler, M. H., Bruchertseifer, F., Morgenstern, A., ... Chérel, M. (2015). Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis. *Front Med (Lausanne)*, 2, 88.
- 52 Despierre, E., Vergote, I., Anderson, R., Coens, C., Katsaros, D., Hirsch, F. R., ... Jimeno, A. (2015). Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. *Target Oncol*, 10, 583-596.

- 53 Diéras, V., Campone, M., Yardley, D. A., Romieu, G., Valero, V., Isakoff, S. J., ... Schmid, P. (2015). Randomized, phase II, placebo-controlled trial of nartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. *Ann. Oncol.*, 26, 1904-1910.
- 54 Djelbani-Ahmed, S., Chandesaris, M. O., Mekinian, A., Canioni, D., Brouzes, C., Hanssens, K., ... Soussan, M. (2015). FDG-PET/CT findings in systemic mastocytosis: a French multicentre study. *Eur. J. Nucl. Med. Mol. Imaging*, 42, 2013-2020.
- 55 Doré, M., Cutuli, B., Cellier, P., Campion, L., & Le Blanc, M. (2015). Hypofractionated irradiation in elderly patients with breast cancer after breast conserving surgery and mastectomy : Analysis of 205 cases. *Radiat Oncol*, 10, 161.
- 56 Doré, M., Lefebvre, L., Delpon, G., & Thillays, F. (2015). [Brain radiation necrosis after stereotactic radiotherapy of the resection cavity for intracranial metastases: analysis of the literature from four cases]. *Cancer Radiother*, 19, 111-119.
- 57 Doré, M., Mahé, M. A., Corradini, N., & Demoor-Goldschmidt, C. (2015). [Neonatal neuroblastoma complicated with a threatening tumoral hepatomegaly treated by irradiation: No sequel 20 years later]. *Cancer Radiother*, 19, 749-751.
- 58 Douillard, J. Y., Siena, S., Peeters, M., Koukakis, R., Terwey, J. H., & Tabernero, J. (2015). Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. *Eur. J. Cancer*, 51, 1231-1242.
- 59 Dumont, F., Goéré, D., Honoré, C., & Elias, D. (2015). Abdominal surgical emergencies in patients with advanced cancer. *J Visc Surg*, 152, S91-96.
- 60 Dumont, F., Goudard, Y., Caramella, C., Goéré, D., Baudin, E., & Elias, D. (2015). Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension. *World J Surg*, 39, 1974-1980.
- 61 Dumont, F., Mariani, A., Elias, D., & Goéré, D. (2015). Surgical strategy for low rectal cancers. *J Visc Surg*, 152, 23-31.
- 62 Dumont, F., Tilly, C., Dartigues, P., Goéré, D., Honoré, C., & Elias, D. (2015). Simple criteria to predict margin involvement after chemoradiotherapy and sphincter-sparing for low rectal cancer. *Eur J Surg Oncol*, 41, 1210-1216.
- 63 Dupouiron, D., Devys, C., Bazin, C., Folliard, C., Lebrec, N., Boré, F., ... Kieffer, H. (2015). Rationale for Prospective Assays of Intrathecal Mixtures Including Morphine, Ropivacaine and Ziconotide: Prevention of Adverse Events and Feasibility in Clinical Practice. *Pain Physician*, 18, 349-357.
- 64 Eberhardt, W. E., De Ruyscher, D., Weder, W., Le Péchoux, C., De Leyn, P., Hoffmann, H., ... Peters, S. (2015). 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. *Ann. Oncol.*, 26, 1573-1588.
- 65 Elias, D., Faron, M., Iuga, B. S., Honoré, C., Dumont, F., Bourgain, J. L., ... Goéré, D. (2015). Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. *Ann. Surg.*, 261, 157-163.
- 66 Escalas, C., Bourdet, C., Fayech, C., & Demoor-Goldschmidt, C. (2015). [Long-term effects of radiation on the spine - Results of a cohort of symptomatic survivors of childhood and review of the literature]. *Bull Cancer*, 102, 684-690.
- 67 Faron, M., Pignon, J. P., Malka, D., Bourredjem, A., Douillard, J. Y., Adenis, A., ... Ducreux, M. (2015). Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. *Eur. J. Cancer*, 51, 166-176.
- 68 Feldmann, A., Langlois, C., Dewailly, M., Martinez, E. F., Boulanger, L., Kerdraon, O., & Faye, N. (2015). Shear Wave Elastography (SWE): An Analysis of Breast Lesion Characterization in 83 Breast Lesions. *Ultrasound Med Biol*, 41, 2594-2604.
- 69 Ferron, G., Simon, L., Guyon, F., Glehen, O., Goere, D., Elias, D., ... Villeneuve, L. (2015). Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey. *Eur J Surg Oncol*, 41, 1361-1367.
- 70 Fichou, N., Gouard, S., Maurel, C., Barbet, J., Ferrer, L., Morgenstern, A., ... Chérel, M. (2015). Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model. *Front Med (Lausanne)*, 2, 76.
- 71 Figarella-Branger, D., Mokhtari, K., Colin, C., Uro-Coste, E., Jouvét, A., Dehais, C., ... Delattre, J. Y. (2015). Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. *Brain Pathol.*, 25, 418-428.
- 72 Fizazi, K., Faivre, L., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., ... Culine, S. (2015). Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. *Lancet Oncol.*, 16, 787-794.
- 73 Fleury, M., Le Vaillant, M., & Pelletier-Fleury, N. (2015). Socio-Economic Status: A Barrier to Access to Mandibular Advancement Device Therapy for Patients with Obstructive Sleep Apnea Syndrome in France. *PLoS ONE*, 10, e0138689.
- 74 Foucher, Y., Meurette, A., Daguin, P., Bonnaud-Antignac, A., Hardouin, J. B., Chailan, S., ... Giral, M. (2015). A personalized follow-up of kidney transplant recipients using video conferencing based on a 1-year scoring system predictive of long term graft failure (TELEGRAFT study): protocol for a randomized controlled trial. *BMC Nephrol*, 16, 6.
- 75 Frenel, J. S., Carreira, S., Goodall, J., Roda, D., Perez-Lopez, R., Tunariu, N., ... de Bono, J. S. (2015). Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. *Clin. Cancer Res.*, 21, 4586-4596.
- 76 Garcia, M. P., Villoing, D., McKay, E., Ferrer, L., Cremonesi, M., Botta, F., ... Bardiès, M. (2015). TestDose: A nuclear medicine software based on Monte Carlo modeling for generating gamma camera acquisitions and dosimetry. *Med Phys*, 42, 6885-6894.
- 77 Geffroy, D., & Doutriaux-Dumoulin, I. (2015). Clinical abnormalities of the nipple-areola complex: The role of imaging. *Diagn Interv Imaging*, 96, 1033-1044.
- 78 Gérard, J. P., Chamorey, E., Gourgou-Bourgade, S., Benezer, K., de Laroche, G., Mahé, M. A., ... Juzyna, B. (2015). Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. *Radiother Oncol*, 115, 246-252.

- 79** Gloaguen, C., Voisin-Chiret, A. S., Sopkova-de Oliveira Santos, J., Fogha, J., Gautier, F., De Giorgi, M., ... Poulain, L. (2015). First evidence that oligopyridines,  $\alpha$ -helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies. *J. Med. Chem.*, 58, 1644-1668.
- 80** Goéré, D., Souadka, A., Faron, M., Cloutier, A. S., Viana, B., Honoré, C., ... Elias, D. (2015). Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. *Ann. Surg. Oncol.*, 22, 2958-2964.
- 81** Goineau, A., Colombié, M., Rousseau, C., Sadot-Lebouvier, S., & Supiot, S. (2015). Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18F-FDG in a Patient With Prostate Cancer. *Clin Nucl Med*, 40, 670-671.
- 82** Goineau, A., d'Aillières, B., de Decker, L., & Supiot, S. (2015). Integrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None? *Front Oncol*, 5, 227.
- 83** Goineau, A., Piot, B., Malard, O., Ferron, C., Lisbona, A., Cassagnau, E., ... Bardet, E. (2015). Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue. *Brachytherapy*, 14, 71-76.
- 84** Gonçalves, A., Pierga, J. Y., Ferrero, J. M., Mouret-Reynier, M. A., Bachelot, T., Delva, R., ... Roché, H. (2015). UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. *Ann. Oncol.*, 26, 1692-1697.
- 85** Gorin, J. B., Gouard, S., Ménager, J., Morgenstern, A., Bruchertseifer, F., Faivre-Chauvet, A., ... Gaschet, J. (2015). Alpha Particles Induce Autophagy in Multiple Myeloma Cells. *Front Med (Lausanne)*, 2, 74.
- 86** Gouveia, L., Lelorain, S., Brédart, A., Dolbeault, S., Bonnaud-Antignac, A., Cousson-Gélie, F., & Sultan, S. (2015). Oncologists' perception of depressive symptoms in patients with advanced cancer: accuracy and relational correlates. *BMC Psychol*, 3, 6.
- 87** Gravis, G., Boher, J. M., Fizazi, K., Joly, F., Priou, F., Marino, P., ... Oudard, S. (2015). Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. *Eur. Urol.*, 68, 196-204.
- 88** Gravis, G., Boher, J. M., Joly, F., Soulié, M., Albiges, L., Priou, F., ... Fizazi, K. (2015). Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. *Eur. Urol.*
- 89** Greilsamer, T., Blanchard, C., Christou, N., Drui, D., Ansquer, C., Le Bras, M., ... Mirallié, E. (2015). Management of thyroid nodules incidentally discovered on MIBI scanning for primary hyperparathyroidism. *Langenbecks Arch Surg*, 400, 313-318.
- 90** Guerard, F., Barbet, J., Chatal, J. F., Kraeber-Bodere, F., Cherel, M., & Haddad, F. (2015). Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy? *Q J Nucl Med Mol Imaging*, 59, 161-167.
- 91** Guette, C., Valo, I., Vétillard, A., & Coqueret, O. (2015). Olfactomedin-4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers. *Proteomics Clin Appl*, 9, 58-63.
- 92** Guiu, S., Charon-Barra, C., Vernerey, D., Fumoleau, P., Campone, M., Spielmann, M., ... Lacroix-Triki, M. (2015). Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial. *Future Oncol*, 11, 2283-2297.
- 93** Gustin, P., Yossi, S., Lafont, M., Peyraga, G., Trémolières, P., Rousseau, D., ... Mesgouez-Nebout, N. (2015). [Use of chemotherapy and radiotherapy in the treatment of urothelial carcinoma of the upper urinary tract]. *Cancer Radiother*, 19, 120-126.
- 94** Halime, Z., Frindel, M., Camus, N., Orain, P. Y., Lacombe, M., Chérel, M., ... Tripiet, R. (2015). New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative. *Org. Biomol. Chem.*, 13, 11302-11314.
- 95** Hanssens, S., Rubod, C., Kerdraon, O., Vinatier, D., Lucot, J. P., Duhamel, A., & Collinet, P. (2015). Pelvic endometriosis in women under 25: a specific management? *Minerva Med.*, 106, 123-131.
- 96** Hecht, J. R., Douillard, J. Y., Schwartzberg, L., Grothey, A., Kopetz, S., Rong, A., ... Sidhu, R. (2015). Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. *Cancer Treat. Rev.*, 41, 653-659.
- 97** Honoré, C., Amroun, K., Vilcot, L., Mir, O., Domont, J., Terrier, P., ... Bonvalot, S. (2015). Abdominal desmoplastic small round cell tumor: multimodal treatment combining chemotherapy, surgery, and radiotherapy is the best option. *Ann. Surg. Oncol.*, 22, 1073-1079.
- 98** Houédé, N., Beuzebec, P., Gourgou, S., Tosi, D., Moise, L., Gravis, G., ... Azria, D. (2015). Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. *BMC Cancer*, 15, 222.
- 99** Jaillardon, L., Abadie, J., Godard, T., Campone, M., Loussouarn, D., Siliart, B., & Nguyen, F. (2015). The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study. *BMC Cancer*, 15, 664.
- 100** Jary, M., Borg, C., Bouché, O., Kim, S., André, T., & Bennouna, J. (2015). [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?]. *Bull Cancer*, 102, 758-771.
- 101** Jauffret, C., Houvenaeghel, G., Classe, J. M., Garbay, J. R., Giard, S., Charitansky, H., ... Lambaudie, É. (2015). [Lobular invasive breast cancer prognostic factors: About 940 patients]. *Gynecol Obstet Fertil*, 43, 712-717.
- 102** Jézéquel, P., Loussouarn, D., Guérin-Charbonnel, C., Campion, L., Vanier, A., Gouraud, W., ... Campone, M. (2015). Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. *Breast Cancer Res.*, 17, 43.
- 103** Jézéquel, P., Sharif, Z., Lasla, H., Gouraud, W., Guérin-Charbonnel, C., Campion, L., ... Campone, M. (2015). Gene-expression signature functional annotation of breast cancer tumours in function of age. *BMC Med Genomics*, 8, 80.

- 104 Joly, F., Delva, R., Mourey, L., Sevin, E., Bompas, E., Vedrine, L., ... Oudard, S. (2015). Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. *BJU Int.*, 115, 65-73.
- 105 Jonchère, B., Vétillard, A., Toutain, B., Lam, D., Bernard, A. C., Henry, C., ... Coqueret, O. (2015). Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1. *Oncotarget*, 6, 409-426.
- 106 Joulin, O., Jeanne, M., & Mavoungou, P. (2015). 20th Meeting of the Société francophone pour l'informatique et le monitoring en anesthésie-réanimation (Sfimar). *Anaesth Crit Care Pain Med*, 34, 115-116.
- 107 Juvalta, S., Post, M. W., Charlifue, S., Noreau, L., Whiteneck, G., Dumont, F. S., & Reinhardt, J. D. (2015). Development and cognitive testing of the Nottwil Environmental Factors Inventory in Canada, Switzerland and the USA. *J Rehabil Med*, 47, 618-625.
- 108 Kervoëlen, C., Ménoret, E., Gomez-Bougie, P., Bataille, R., Godon, C., Marionneau-Lambot, S., ... Amiot, M. (2015). Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma. *Oncotarget*, 6, 26922-26934.
- 109 Khalifa, J., Ouali, M., Chaltiel, L., Le Guellec, S., Le Cesne, A., Blay, J. Y., ... Chevreau, C. (2015). Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. *BMC Cancer*, 15, 700.
- 110 Kraeber-Bodéré, F., Rousseau, C., Bodet-Milin, C., Frampas, E., Favier-Chauvet, A., Rauscher, A., ... Barbet, J. (2015). A pretargeting system for tumor PET imaging and radioimmunotherapy. *Front Pharmacol*, 6, 54.
- 111 Kraeber-Bodéré, F., Rousseau, C., Bodet-Milin, C., Mathieu, C., Guérard, F., Frampas, E., ... Barbet, J. (2015). Tumor immunotargeting using innovative radionuclides. *Int J Mol Sci*, 16, 3932-3954.
- 112 Kramar, A., Negrier, S., Sylvester, R., Joniau, S., Mulders, P., Powles, T., ... Filleron, T. (2015). Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. *Ann. Oncol.*, 26, 2392-2398.
- 113 Krause, M., & Supiot, S. (2015). Advances in radiotherapy special feature. *Br J Radiol*, 88, 20150412.
- 114 Krause, M., & Supiot, S. (2015). Advances in Radiotherapy special feature. *Br J Radiol*, 20150412.
- 115 Krop, I. E., Suter, T. M., Dang, C. T., Dirix, L., Romieu, G., Zamagni, C., ... Gianni, L. (2015). Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. *J. Clin. Oncol.*, 33, 1136-1142.
- 116 Kuchenbaecker, K. B., Ramus, S. J., Tyrer, J., Lee, A., Shen, H. C., Beesley, J., ... Chenevix-Trench, G. (2015). Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat. Genet.*, 47, 164-171.
- 117 Laas, E., Touboul, C., Kerdraon, O., & Catteau-Jonard, S. (2015). [Inflammatory and infectious breast mastitis outside of pregnancy and lactation: Guidelines]. *J Gynecol Obstet Biol Reprod (Paris)*, 44, 996-1016.
- 118 Labreche, K., Simeonova, I., Kamoun, A., Gleize, V., Chubb, D., Letouzé, E., ... Houlston, R. S. (2015). TCF12 is mutated in anaplastic oligodendroglioma. *Nat Commun*, 6, 7207.
- 119 Lartigau, É., Lisbona, A., Isambert, A., Cadot, P., Derreumaux, S., Dupuis, O., ... Aubert, B. (2015). [Implementing new technology in radiation oncology: The French agency for nuclear safety (ASN) report]. *Cancer Radiother*, 19, 616-620.
- 120 Lavoué, V., Fritel, X., Antoine, M., Beltjens, F., Bendifallah, S., Boisserie-Lacroix, M., ... Daraï, E. (2015). [Benign breast tumors: Recommendations of Collège National des Gynécologues Obstétriciens Français (CNGOF)--Short text]. *J Gynecol Obstet Biol Reprod (Paris)*, 44, 1049-1064.
- 121 Le Cesne, A., Ray-Coquard, I., Duffaud, F., Chevreau, C., Penel, N., Bui Nguyen, B., ... Yves Blay, J. (2015). Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. *Eur. J. Cancer*, 51, 742-750.
- 122 Le Tourneau, C., Delord, J. P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., ... Paoletti, X. (2015). Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. *Lancet Oncol.*, 16, 1324-1334.
- 123 Lecarpentier, J., Noguès, C., Mouret-Fourme, E., Buecher, B., Gauthier-Villars, M., Stoppa-Lyonnet, D., ... Andrieu, N. (2015). Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers. *Cancer Epidemiol. Biomarkers Prev.*, 24, 698-707.
- 124 Lelorain, S., Brédart, A., Dolbeault, S., Cano, A., Bonnaud-Antignac, A., Cousson-Gélie, F., & Sultan, S. (2015). How does a physician's accurate understanding of a cancer patient's unmet needs contribute to patient perception of physician empathy? *Patient Educ Couns*, 98, 734-741.
- 125 Lepoutre-Lussey, C., Caramella, C., Bidault, F., Déandreis, D., Berdelou, A., Al Ghuzlan, A., ... Lebouleux, S. (2015). Screening in asymptomatic SDHx mutation carriers: added value of <sup>18</sup>F-FDG PET/CT at initial diagnosis and 1-year follow-up. *Eur. J. Nucl. Med. Mol. Imaging*, 42, 868-876.
- 126 Levoyn, N., Vo, D. D., Gautier, F., Barillé-Nion, S., Juin, P., Tasseau, O., & Grée, R. (2015). A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors. *Bioorg. Med. Chem.*, 23, 1747-1757.
- 127 Levy, A., Azria, D., Pignon, J. P., Delarochefordiere, A., Martel-Lafay, I., Rio, E., ... Deutsch, E. (2015). Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. *Radiother Oncol*, 114, 415-416.
- 128 Lévy, C., Allouache, D., Lacroix, J., Dugué, A. E., Supiot, S., Campone, M., ... Paoletti, X. (2015). REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. *Ann. Oncol.*, 26, 2359.
- 129 Lisbona, A., & Valero, M. (2015). [Practical risk analysis]. *Cancer Radiother*, 19, 629-633.
- 130 Locke, J. A., Dal Pra, A., Supiot, S., Warde, P., & Bristow, R. G. (2015). Synergistic action of image-guided radiotherapy and androgen deprivation therapy. *Nat Rev Urol*, 12, 193-204.

- 131** Machiels, J. P., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Vermorken, J. B., ... Cohen, E. E. (2015). Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. *Lancet Oncol.*, 16, 583-594.
- 132** Malard, O., Lanhouet, J., Michel, G., Dreno, B., Espitalier, F., & Rio, E. (2015). Full-thickness nasal defect: place of prosthetic reconstruction. *Eur Ann Otorhinolaryngol Head Neck Dis*, 132, 85-89.
- 133** Marcy, P. Y., Dahlet, C., Brenet, O., Yazbec, G., Dubois, P. Y., Salm, B., ... Chamorey, E. (2015). [Multicenter validation study of a questionnaire assessing patient satisfaction with and acceptance of totally-implanted central venous access devices]. *Bull Cancer*, 102, 301-315.
- 134** Mariette, C., Gronnier, C., Duhamel, A., Mabrut, J. Y., Bail, J. P., Carrere, N., ... Piessen, G. (2015). Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes. *J. Am. Coll. Surg.*, 220, 287-296.
- 135** Marino, P., Houvenaeghel, G., Narducci, F., Boyer-Chammard, A., Ferron, G., Uzan, C., ... Lambaudie, E. (2015). Cost-Effectiveness of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications. *Int. J. Gynecol. Cancer*, 25, 1102-1108.
- 136** Mathieu, C., Ferrer, L., Carlier, T., Colombié, M., Rusu, D., Kraeber-Bodéré, F., ... Rousseau, C. (2015). Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer. *Front Med (Lausanne)*, 2, 67.
- 137** Melichar, B., Adenis, A., Lockhart, A. C., Bennouna, J., Dees, E. C., Kayaleh, O., ... Schusterbauer, C. (2015). Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. *Lancet Oncol.*, 16, 395-405.
- 138** Ménager, J., Gorin, J. B., Maurel, C., Drujont, L., Gouard, S., Louvet, C., ... Guilloux, Y. (2015). Combining  $\alpha$ -Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction. *PLoS ONE*, 10, e0130249.
- 139** Moreau, M., Buvat, I., Ammour, L., Chouin, N., Kraeber-Bodéré, F., Chérel, M., & Carlier, T. (2015). Assessment of a fully 3D Monte Carlo reconstruction method for preclinical PET with iodine-124. *Phys Med Biol*, 60, 2475-2491.
- 140** Moro-Sibilot, D., Audigier-Valette, C., Merle, P., Quoix, E., Souquet, P. J., Barlesi, F., ... Zalcman, G. (2015). Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). *Lung Cancer*, 89, 139-145.
- 141** Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., ... Sharma, P. (2015). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.*, 373, 1803-1813.
- 142** Novello, S., Kaiser, R., Mellemegaard, A., Douillard, J. Y., Orlov, S., Krzakowski, M., ... Reck, M. (2015). Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. *Eur. J. Cancer*, 51, 317-326.
- 143** Oger, A. S., Boukerrou, M., Cutuli, B., Campion, L., Rousseau, E., Bussièrès, E., ... Classe, J. M. (2015). [Male breast cancer: prognostic factors, diagnosis and treatment: a multi-institutional survey of 95 cases]. *Gynecol Obstet Fertil*, 43, 290-296.
- 144** Oger, A. S., Classe, J. M., Ingster, O., Morin-Meschin, M. E., Sauterey, B., Lorimier, G., ... Raro, P. (2015). [Prophylactic surgery in patients mutated BRCA or high risk: retrospective study of 61 patients in the ICO]. *Ann Chir Plast Esthet*, 60, 19-25.
- 145** Oudard, S., Kramer, G., Caffo, O., Creppy, L., Loriot, Y., Hansen, S., ... Krainer, M. (2015). Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. *BJU Int.*, 115, 744-752.
- 146** Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., ... Perren, T. J. (2015). Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. *Lancet Oncol.*, 16, 928-936.
- 147** Pacaud, R., Cheray, M., Nadaradjane, A., Vallette, F. M., & Cartron, P. F. (2015). Histone H3 phosphorylation in GBM: a new rationale to guide the use of kinase inhibitors in anti-GBM therapy. *Theranostics*, 5, 12-22.
- 148** Pautier, P., Floquet, A., Chevreau, C., Penel, N., Guillemet, C., Delcambre, C., ... Duffaud, F. (2015). Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. *Lancet Oncol.*, 16, 457-464.
- 149** Peeters, M., Karthaus, M., Rivera, F., Terwey, J. H., & Douillard, J. Y. (2015). Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. *Drugs*, 75, 731-748.
- 150** Pellier, I., Renier, G., Rakotonjanahary, J., Audrain, M., Berardi, E., Gardembas, M., ... Jeannin, P. (2015). Long-term consequences of Hodgkin lymphoma therapy on T-cell lymphopoiesis. *J. Allergy Clin. Immunol.*, 135, 818-820.e814.
- 151** Peterlongo, P., Chang-Claude, J., Moysich, K. B., Rudolph, A., Schmutzler, R. K., Simard, J., ... Friedman, E. (2015). Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol. Biomarkers Prev.*, 24, 308-316.
- 152** Peyraga, G., Capitain, O., Rousseau, D., Rio, E., Septans, A. L., Baton, O., ... Paumier, A. (2015). [Are extensive fields useful for radiotherapy of esophageal cancer?]. *Cancer Radiother*, 19, 313-321.
- 153** Philippe, Y., Espitalier, F., Durand, N., Ferron, C., Bardet, É., & Malard, O. (2015). Authors' response to the letter on the article "Partial laryngectomy as salvage surgery after radiotherapy: Oncological and functional outcomes and impact on quality of life. A retrospective study of 20 cases". *Eur Ann Otorhinolaryngol Head Neck Dis*, 132, 373.
- 154** Pierga, J. Y., Petit, T., Lévy, C., Ferrero, J. M., Campone, M., Gligorov, J., ... Viens, P. (2015). Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. *Clin. Cancer Res.*, 21, 1298-1304.
- 155** Polack, B., Calvez, T., Chambost, H., Rothschild, C., Goudemand, J., Claeysens, S., ... Woronoff-Lemsi, M. C. (2015). EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France. *Transfusion*, 55, 1787-1797.

- 156** Pujol, J. L., Vansteenkiste, J. F., De Pas, T. M., Atanackovic, D., Reck, M., Thomeer, M., ... Lehmann, F. F. (2015). Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. *J Thorac Oncol*, 10, 1458-1467.
- 157** Rauscher, A., Frindel, M., Rajerison, H., Gouard, S., Maurel, C., Barbet, J., ... Mougou-Degraef, M. (2015). Improvement of the Targeting of Radiolabeled and Functionalized Liposomes with a Two-Step System Using a Bispecific Monoclonal Antibody (Anti-CEA x Anti-DTPA-In). *Front Med (Lausanne)*, 2, 83.
- 158** Ravaud, A., Oudard, S., De Fromont, M., Chevreau, C., Gravis, G., Zanetta, S., ... Escudier, B. (2015). First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. *Ann. Oncol.*, 26, 1123-1128.
- 159** Ray-Coquard, I. L., Domont, J., Tresch-Bruneel, E., Bompas, E., Cassier, P. A., Mir, O., ... Penel, N. (2015). Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. *J. Clin. Oncol.*, 33, 2797-2802.
- 160** Reck, M., Mellemegaard, A., von Pawel, J., Gottfried, M., Bondarenko, I., Cheng, Y., ... Douillard, J. Y. (2015). Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. *Lung Cancer*, 90, 267-273.
- 161** Rigaud, J., Leger, A., Devilder, M. C., Bouchot, O., Bonneville, M., & Scotet, E. (2015). Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Guérin Instillations for Bladder Cancer. *Clin Genitourin Cancer*, 13, e209-215.
- 162** Rollin, J., Payancé, A., Gouilleux-Gruart, V., Boisdron-Celle, M., Azzopardi, N., Morel, A., ... Lecomte, T. (2015). Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. *Pharmacogenomics*, 16, 2035-2043.
- 163** Rusu, D., Carlier, T., Colombié, M., Goulon, D., Fleury, V., Rousseau, N., ... Rousseau, C. (2015). Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up. *Front Med (Lausanne)*, 2, 46.
- 164** Saad, F., Fizazi, K., Jinga, V., Efstathiou, E., Fong, P. C., Hart, L. L., ... de Wit, R. (2015). Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. *Lancet Oncol.*, 16, 338-348.
- 165** Saito, K., Pignon, P., Ayyoub, M., & Valmori, D. (2015). Modulation of Cytokine Secretion Allows CD4 T Cells Secreting IL-10 and IL-17 to Simultaneously Participate in Maintaining Tolerance and Immunity. *PLoS ONE*, 10, e0145788.
- 166** Sargos, P., Guerif, S., Latorzeff, I., Hennequin, C., Pommier, P., Lagrange, J. L., ... Richaud, P. (2015). Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU). *Cancer Treat. Rev.*, 41, 814-820.
- 167** Scarlata, C. M., Celse, C., Pignon, P., Ayyoub, M., & Valmori, D. (2015). Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells. *Eur. J. Immunol.*, 45, 474-479.
- 168** Schneiders, F. L., Huijts, C. M., Mantici, A., Menks, M. A., Scotet, E., Veerhuis, R., ... van der Vliet, H. J. (2015). Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. *Clin. Immunol.*, 158, 92-99.
- 169** Schwob, L., Koumeir, C., Servagent, N., Cherel, M., Guertin, A., Haddad, F., ... Varmentot, N. (2015). New beam monitoring tool for radiobiology experiments at the cyclotron ARRONAX. *Radiat Prot Dosimetry*, 166, 257-260.
- 170** Segaliny, A. I., Brion, R., Mortier, E., Maillason, M., Cherel, M., Jacques, Y., ... Heymann, D. (2015). Syndecan-1 regulates the biological activities of interleukin-34. *Biochim. Biophys. Acta*, 1853, 1010-1021.
- 171** Selvam, B., Graton, J., Laurent, A. D., Alamiddine, Z., Mathé-Allainmat, M., Lebreton, J., ... Le Questel, J. Y. (2015). Imidacloprid and thiacloprid neonicotinoids bind more favourably to cockroach than to honeybee  $\alpha 6$  nicotinic acetylcholine receptor: insights from computational studies. *J. Mol. Graph. Model.*, 55, 1-12.
- 172** Serdjebi, C., Gagnière, J., Desramé, J., Fein, F., Guimbaud, R., François, E., ... Dahan, L. (2015). FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. *PLoS ONE*, 10, e0135907.
- 173** Shi, Q., de Gramont, A., Grothey, A., Zalberg, J., Chibaudel, B., Schmoll, H. J., ... Sargent, D. J. (2015). Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. *J. Clin. Oncol.*, 33, 22-28.
- 174** Solal-Celigny, P. (2015). Rituximab by subcutaneous route. *Expert Rev Hematol*, 8, 147-153.
- 175** Sorin, T., Fyad, J. P., Delay, E., Rouanet, P., Rimareix, F., Houpeau, J. L., ... Marchal, F. (2015). Occult cancer in specimens of reduction mammoplasty aimed at symmetrization. A multicentric study of 2718 patients. *Breast*, 24, 272-277.
- 176** Sourrouille, I., Vilcot, L., Honoré, C., Coppola, S., Terrier, P., le Cesne, A., ... Bonvalot, S. (2015). Algorithm for the surgical management of mesenchymal tumors of the perineum in adults. *Dis. Colon Rectum*, 58, 304-313.
- 177** Sternberg, C. N., Skoneczna, I., Kerst, J. M., Albers, P., Fossa, S. D., Agerbaek, M., ... Sylvester, R. (2015). Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ MO urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. *Lancet Oncol.*, 16, 76-86.
- 178** Supiot, S., Clément-Colmou, K., Paris, F., Corre, I., Chiavassa, S., & Delpou, G. (2015). [Which rules apply to hypofractionated radiotherapy?]. *Cancer Radiother*, 19, 421-425.



- 179** Supiot, S., Rio, E., Pacteau, V., Mauboussin, M. H., Campion, L., & Pein, F. (2015). OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. *BMC Cancer*, 15, 646.
- 180** Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., ... Cortés, J. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N. Engl. J. Med.*, 372, 724-734.
- 181** Taleb, S., Saada-Bouzid, E., Tresch, E., Ryckewaert, T., Bompas, E., Italiano, A., ... Penel, N. (2015). Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. *Eur. J. Cancer*, 51, 202-209.
- 182** Takahashi, Y., Vagge, S., Agostinelli, S., Han, E., Matulewicz, L., Schubert, K., ... Hui, S. K. (2015). Multi-institutional feasibility study of a fast patient localization method in total marrow irradiation with helical tomotherapy: a global health initiative by the international consortium of total marrow irradiation. *Int. J. Radiat. Oncol. Biol. Phys.*, 91, 30-38.
- 183** Taniguchi, Y., Takahashi, Y., Toba, T., Yamada, S., Yokoi, K., Kobayashi, S., ... Kaufmann, P. A. (2015). Poster Session 1: Sunday 3 May 2015, 08:30-18:00 Room: Poster Area. *Eur Heart J Cardiovasc Imaging*, 16, i11-i28.
- 184** Trédan, O., Campone, M., Jassem, J., Vyzula, R., Coudert, B., Pacillo, C., ... Roché, H. (2015). Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. *Clin. Breast Cancer*, 15, 8-15.
- 185** Treilleux, I., Arnedos, M., Cropet, C., Wang, Q., Ferrero, J. M., Abadie-Lacourtoisie, S., ... Bachelot, T. (2015). Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. *Ann. Oncol.*, 26, 120-125.
- 186** Tsao, M. S., Marguet, S., Le Teuff, G., Lantuejoul, S., Shepherd, F. A., Seymour, L., ... Brambilla, E. M. (2015). Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. *J. Clin. Oncol.*, 33, 3439-3446.
- 187** Tuffal, A., Moulin, S., Dequatre-Ponchelle, N., Bodenent, M., Dumont, F., Lefebvre, C., ... Leys, D. (2015). Influence of neurologists' experience on the outcome of patients treated by intravenous thrombolysis for cerebral ischaemia. *J. Neurol.*, 262, 1209-1215.
- 188** Valmori, D., & Ayyoub, M. (2015). CD4(+) T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs. *Oncoimmunology*, 4, e946370.
- 189** Van Cutsem, E., Prenen, H., D'Haens, G., Bannoun, J., Carrato, A., Ducreux, M., ... Capdevila, J. (2015). A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. *Ann. Oncol.*, 26, 2085-2091.
- 191** Van den Berg, H., Paulussen, M., Le Teuff, G., Judson, I., Gelderblom, H., Dirksen, U., ... Le Deley, M. C. (2015). Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. *Eur. J. Cancer*, 51, 2453-2464.
- 191** Vansteenkiste, J., Barlesi, F., Waller, C. F., Bannoun, J., Gridelli, C., Goekkur, E., ... O'Byrne, K. (2015). Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). *Ann. Oncol.*, 26, 1734-1740.
- 192** Vendrely, V., Henriques de Figueiredo, B., Rio, E., Benech, J., Belhomme, S., Lisbona, A., ... Maire, J. P. (2015). French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients. *Radiat Oncol*, 10, 170.
- 193** Véquaud, E., Séveno, C., Loussouarn, D., Engelhart, L., Campone, M., Juin, P., & Barillé-Nion, S. (2015). YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-κB network. *Oncotarget*, 6, 13476-13486.
- 194** Vétillard, A., Jonchère, B., Moreau, M., Toutain, B., Henry, C., Fontanel, S., ... Coqueret, O. (2015). Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis. *Oncotarget*, 6, 43342-43362.
- 195** Vincent, J., Mariette, C., Pezet, D., Huet, E., Bonnetain, F., Bouché, O., ... Bedenne, L. (2015). Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFC09102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone. *Eur. J. Cancer*, 51, 1683-1693.
- 196** Yang, J. C., Wu, Y. L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., ... Sequist, L. V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol.*, 16, 141-151.
- 197** Yossi, S., El Alouani, C., Pointreau, Y., Laccourreye, L., Capitain, O., Gustin, P., ... Tuchais, C. (2015). [Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract]. *Cancer Radiother*, 19, 73-81.
- 198** Yossi, S., Krhili, S., Muratet, J. P., Septans, A. L., Campion, L., & Denis, F. (2015). Early assessment of metabolic response by 18F-FDG PET during concomitant radiochemotherapy of non-small cell lung carcinoma is associated with survival: a retrospective single-center study. *Clin Nucl Med*, 40, e215-221.
- 199** Yossi, S., Linot, B., Peyraga, G., Breheret, R., Laccourreye, L., & Capitain, O. (2015). Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study. *Int. J. Clin. Oncol.*, 20, 1086-1092.